Primary Therapy With Single Agent Bortezomib as Induction, Maintenance and Re-Induction in Patients With High-Risk Myeloma: Results of the ECOG E2A02 Trial

Leukemia - United Kingdom
doi 10.1038/leu.2010.129
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Bortezomib Just for Induction or Also for Maintenance in Myeloma Patients With Renal Impairment?

Haematologica
Hematology
2014English

Efficacy and Safety of Reduced-Intensity Induction Therapy With a Bortezomib-Based Regimen in Elderly Patients With Multiple Myeloma

Therapeutic Advances in Hematology
Hematology
2012English

Cytogenetic Features and Clinical Outcomes of Patients With Non-Secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2020English

Efficacy of Single-Agent Bortezomib vs. Single-Agent Thalidomide in Patients With Relapsed or Refractory Multiple Myeloma: A Systematic Comparison

European Journal of Haematology
MedicineHematology
2007English

Induction Therapy and Stem Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma

Stem Cells International
Cell BiologyMolecular Biology
2012English

Peripheral Neuropathy Induced by Subcutaneous Bortezomib-Based Induction Therapy for Newly Diagnosed Multiple Myeloma

Haematologica
Hematology
2014English

Fatal Cardiovascular Collapse Following Propofol Induction in High-Risk Patients and Dilemmas in the Selection of a Short-Acting Induction Agent

Anaesthesia and Intensive Care
Critical CareAnesthesiologyPain MedicineIntensive Care Medicine
1995English

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Cancer
Cancer ResearchOncology
2016English

ADE as Induction Therapy Results in Treatment of Children With Non-M3 High-Risk Acute Myeloid Leukemia, an Extrapolable Achievement in Developing Countries

Journal of Cancer Therapy
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy